Alpha-1
Revolutionizing AATD Treatment: Emerging Therapies to Replace Augmentation Therapy
Alpha-1 Antitrypsin Deficiency (AATD), Genetic Disorder, New Therapies, Augmentation Therapy, RNA Interference (RNAi), Gene Editing, CRISPR
Vertex Pharmaceuticals Abandons Two Phase I AATD Drug Candidates Due to Disappointing Data
Vertex Pharmaceuticals, AATD, alpha-1 antitrypsin deficiency, drug candidates, Phase I trials, disappointing data
Biotech Startup Airna Secures $60M to Advance RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency
Airna, RNA editing, alpha-1 antitrypsin deficiency, AATD, biotech startup, genetic medicine, ADAR, CRISPR, RNA therapy